Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Gemfibrozil (Pilder; CI-719; CI719; CI 719; Lopid; Jezil; Lipur; Trialmin) is a potent anti-hypertriglyceridemic/lipid lowering drug acting as an activator/agonist of peroxisome proliferator-activated receptor-alpha (PPARα). It has been approved for the treatment of hypercholesterolemia and hypertriglyceridemia.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
J Pharmacol Exp Ther.2002 Jun;301(3):1042-51;Drug Metab Dispos.2001 Nov;29(11):1359-61.
|
Molecular Formula |
C15H22O3
|
|
---|---|---|
Molecular Weight |
250.33
|
|
CAS # |
25812-30-0
|
|
Related CAS # |
Gemfibrozil;25812-30-0
|
|
SMILES |
O(C1C([H])=C(C([H])([H])[H])C([H])=C([H])C=1C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C(C(=O)O[H])(C([H])([H])[H])C([H])([H])[H]
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.9947 mL | 19.9736 mL | 39.9473 mL | |
5 mM | 0.7989 mL | 3.9947 mL | 7.9895 mL | |
10 mM | 0.3995 mL | 1.9974 mL | 3.9947 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02638597 | Completed Has Results | Drug: Gemfibrozil Behavioral: smoking cessation counseling |
Smoking Cessation | University of Texas Southwestern Medical Center |
February 2015 | Phase 2 |
NCT01385020 | Completed | Drug: Gemfibrozil & red yeast rice (LipoCol) |
Healthy Subjects | National Taiwan University Hospital | July 2011 | Phase 4 |
NCT01876810 | Completed Has Results | Drug: Gemfibrozil Drug: Placebo |
Nicotine Dependence | Centre for Addiction and Mental Health | February 2014 | Phase 2 |
NCT03539432 | Terminated Has Results | Drug: Gemfibrozil 600 MG Drug: Placebo oral capsule |
Alcohol Use Disorder | The Mind Research Network | May 16, 2018 | Phase 2 |
Time course of cytokine-induced NO production and its suppression by gemfibrozil in human U373MG astroglial cells td> |
Gemfibrozil dose-dependently inhibits the expression of iNOS in cytokine-stimulated human U373MG astroglial cells td> |
Effect of gemfibrozil on the stability of iNOS mRNA in human U373MG astroglial cells td> |